The case for & against
Bull & Bear analysis
Bullish
Haemonetics Corporation (NYSE: HAE) is a leading player in the medical device industry, specializing in blood management, plasma collection, and interventional technologies. The company is well-positioned within a growing sector that is solidified by increasing demand for plasma-derived therapies and enhanced operational efficiencies. Haemonetics’ focus on innovation, particularly through its product platforms like Persona Plus and the newly introduced Percocil Elite, exemplifies its commitment to maintaining market leadership amidst a competitive landscape.
Bull says
- ↑Q4 2026 revenue $346M (+5% YoY; +9% organic ex-CSL)
- ↑Adjusted EPS rose 4% to $1.29; free cash flow $210M (89% conversion)
- ↑Persona Plus introduced; Percocil Elite expected to drive 4–7% FY27 growth
- ↑Allocated $175M to share buybacks, bolstering shareholder returns
- ↑BTIG Buy rating with $84 target reflects strong analyst confidence
- ↑High earnings yield and solid liquidity underpin trading support
Bear says
- ↓Interventional technologies revenue declined 5% in Q4, signaling segment risk
- ↓Tariffs accounted for ~60% of annual cost impact, squeezing margins
- ↓Negative profitability factors and downward earnings revisions raise stability concerns
- ↓Full-year revenue fell 2% due to portfolio transitions and pricing pressure
- ↓Intense competition in plasma & vascular closure markets threatens pricing
- ↓Declining momentum and revision indicators reflect negative investor sentiment
Investment themes with HAE
Buybacks↑ +0.48%
Companies repurchasing their own shares
C · JCI · WFC
Earnings Call · Q4 2025 · Mgmt. Guidance
Updated 05-29-2026neutral
Transcript signals
Read full transcript analysis ›